Bronchogen

How a course is commonly described

1. 1
   Days 1-10Community-reported

   Community protocols begin and stay at a flat microgram dose, most often 200 to 400 mcg a day by mouth, with no titration described. Ten days is the shortest course length in circulation and the convention comes from the Khavinson supplement line rather than from any study.

2. 2
   Days 10-30Community-reported

   The full course described online runs 10 to 30 days at the same dose, sometimes paired with chonluten, a different and shorter peptide the same group also links to bronchial cells. No human measurement exists at any point in this window.

3. 3
   Break, then 2-3 courses a yearCommunity-reported

   Courses are repeated two or three times a year with long gaps between them, which guides justify by a presumed lasting change in gene expression rather than by any measured persistence. Some community pages tie the timing to the start of the respiratory infection season.

4. 4
   Preclinical comparison, 1 monthPreclinical

   The only in vivo timeline is the rat model: after 60 days of nitrogen dioxide exposure had produced the disease, one month of treatment reversed the airway remodelling and raised secretory IgA. The paper does not state the dose or the route in its English abstract, so the one-month figure is the only part of that protocol that transfers.

• No human study of bronchogen has been published and no trial is registered. The microgram capsule doses and 10 to 30 day courses in circulation come from the Russian supplement line, and the only published quantities are culture concentrations such as 0.05 ng/mL.
• There are no pharmacokinetic data for any route in any species. The rat study does not state its dose or route in English, the cell work was done by adding peptide to medium, and the argument for oral absorption rests on a 2023 computer docking model.
• Almost all of the research comes from one St Petersburg group and its collaborators, much of it in Russian-language journals, and no independent laboratory has replicated the lung findings.
• The research itself raises the open safety questions: the peptide stimulates bronchial cell proliferation most strongly in aged cultures, raises an anti-apoptotic protein and increases expression of the main airway mucin, and it has not been through a standard genotoxicity assay despite binding DNA and loosening nucleosomes. It is not named on the WADA prohibited list.